Otsuka's VOYXACT Stabilizes Kidney Function in IgA Nephropathy Phase 3 Trial — Otsuka Pharmaceutical Co., Ltd.

Event summary

Otsuka's VOYXACT (sibeprenlimab-szsi) demonstrated stabilization of kidney function decline to baseline physiologic rate in IgA Nephropathy patients over two years.
Phase 3 VISIONARY trial met key secondary endpoint with annualized eGFR slope of +0.3 mL/min/1.73 m²/year for VOYXACT vs -4.2 for placebo (p<0.0001).
VOYXACT is the first IgAN treatment to achieve KDIGO's therapeutic goal of halting progressive kidney function decline.
Safety profile remained consistent through two years with no new safety signals identified.

The big picture

Otsuka's results position VOYXACT as a potentially transformative therapy for IgA Nephropathy, addressing an unmet need in a progressive kidney disease with limited treatment options. The stabilization of eGFR decline represents a significant clinical advancement, potentially altering the standard of care for this patient population. This success builds on Otsuka's strategic focus in nephrology and immunology, areas where targeted biologics are increasingly demonstrating disease-modifying capabilities.

What we're watching

Regulatory Pathway: Whether the two-year eGFR data will support VOYXACT's traditional FDA approval following its accelerated approval in November 2025.
Market Positioning: How Otsuka positions VOYXACT against potential competitors in the IgAN treatment landscape, particularly as the first selective APRIL inhibitor approved for this indication.
Long-term Efficacy: The pace at which additional data from the open-label extension study (NCT05248659) may further validate VOYXACT's disease-modifying potential in IgAN patients.